2020 Form 10-K Financial Statement
#000156459021011098 Filed on March 05, 2021
Income Statement
| Concept | 2020 | 2019 Q4 | 2019 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $9.540M | $5.110M | |
| YoY Change | 86.69% | 109.43% | |
| % of Gross Profit | |||
| Research & Development | $32.15M | $19.01M | |
| YoY Change | 69.15% | 130.69% | |
| % of Gross Profit | |||
| Depreciation & Amortization | $100.0K | $30.00K | $33.00K |
| YoY Change | 203.03% | ||
| % of Gross Profit | |||
| Operating Expenses | $41.70M | $24.12M | |
| YoY Change | 72.91% | 125.81% | |
| Operating Profit | -$41.70M | -$24.12M | |
| YoY Change | 72.91% | ||
| Interest Expense | $483.0K | $578.0K | |
| YoY Change | -16.44% | ||
| % of Operating Profit | |||
| Other Income/Expense, Net | $338.0K | $653.0K | |
| YoY Change | -48.24% | -198.94% | |
| Pretax Income | -$41.36M | -$23.46M | |
| YoY Change | 76.3% | 106.88% | |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$41.36M | -$23.46M | |
| YoY Change | 76.28% | 106.9% | |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$2.971M | -$1.415M | |
| COMMON SHARES | |||
| Basic Shares Outstanding | |||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 | 2019 Q4 | 2019 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $88.22M | $28.91M | $28.91M |
| YoY Change | 205.15% | 291.73% | |
| Cash & Equivalents | $47.70M | $4.936M | $4.940M |
| Short-Term Investments | $40.52M | $23.97M | $23.97M |
| Other Short-Term Assets | $2.180M | $1.700M | $1.720M |
| YoY Change | 26.74% | 437.5% | |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $90.41M | $30.62M | $30.62M |
| YoY Change | 195.26% | 297.15% | |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $350.0K | $442.0K | $440.0K |
| YoY Change | -20.45% | ||
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $90.00K | $2.232M | $2.230M |
| YoY Change | -95.96% | ||
| Total Long-Term Assets | $430.0K | $2.674M | $2.680M |
| YoY Change | -83.96% | ||
| TOTAL ASSETS | |||
| Total Short-Term Assets | $90.41M | $30.62M | $30.62M |
| Total Long-Term Assets | $430.0K | $2.674M | $2.680M |
| Total Assets | $90.84M | $33.30M | $33.30M |
| YoY Change | 172.79% | 331.91% | |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.970M | $1.658M | $1.660M |
| YoY Change | 18.67% | 82.42% | |
| Accrued Expenses | $4.280M | $2.540M | $2.540M |
| YoY Change | 68.5% | 176.09% | |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $6.250M | $4.198M | $4.200M |
| YoY Change | 48.81% | 129.51% | |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $160.0K | $200.0K | $180.0K |
| YoY Change | -11.11% | ||
| Total Long-Term Liabilities | $160.0K | $200.0K | $180.0K |
| YoY Change | -11.11% | ||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.250M | $4.198M | $4.200M |
| Total Long-Term Liabilities | $160.0K | $200.0K | $180.0K |
| Total Liabilities | $6.410M | $4.382M | $4.380M |
| YoY Change | 46.35% | 139.34% | |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$54.75M | ||
| YoY Change | |||
| Common Stock | $1.000K | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $84.44M | -$48.85M | $28.92M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $90.84M | $33.30M | $33.30M |
| YoY Change | 172.79% | 331.91% |
Cashflow Statement
| Concept | 2020 | 2019 Q4 | 2019 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$41.36M | -$23.46M | |
| YoY Change | 76.28% | 106.9% | |
| Depreciation, Depletion And Amortization | $100.0K | $30.00K | $33.00K |
| YoY Change | 203.03% | ||
| Cash From Operating Activities | -$37.40M | -$14.32M | -$21.88M |
| YoY Change | 70.95% | 211.3% | 149.17% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$20.00K | -$60.00K | -$140.0K |
| YoY Change | -85.71% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$16.70M | -$23.92M | -$23.92M |
| YoY Change | -30.18% | ||
| Cash From Investing Activities | -$16.72M | -$23.98M | -$24.06M |
| YoY Change | -30.5% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 96.88M | -2.000M | 43.58M |
| YoY Change | 122.31% | -130.82% | 571.48% |
| NET CHANGE | |||
| Cash From Operating Activities | -37.40M | -14.32M | -21.88M |
| Cash From Investing Activities | -16.72M | -23.98M | -24.06M |
| Cash From Financing Activities | 96.88M | -2.000M | 43.58M |
| Net Change In Cash | 42.76M | -40.30M | -2.358M |
| YoY Change | -1913.49% | -2232.28% | 2.97% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$37.40M | -$14.32M | -$21.88M |
| Capital Expenditures | -$20.00K | -$60.00K | -$140.0K |
| Free Cash Flow | -$37.38M | -$14.26M | -$21.74M |
| YoY Change | 71.96% | 210.0% | 147.57% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
4382000 | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
47698000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
4936000 | |
| CY2020Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
40524000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
23971000 | |
| CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2183000 | |
| CY2019Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1717000 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
90405000 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
30624000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
349000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
442000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
88000 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2232000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
90842000 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
33298000 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1971000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1658000 | |
| CY2020Q4 | imra |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
4276000 | |
| CY2019Q4 | imra |
Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
|
2540000 | |
| CY2020Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
160000 | |
| CY2019Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
184000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
18000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
180526000 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
4000 | |
| CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2231000 | |
| CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
899000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
17548263 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
702510 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
17548263 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
702510 | |
| CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32154000 | |
| CY2019 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
19009000 | |
| CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9544000 | |
| CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5107000 | |
| CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
41698000 | |
| CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
24116000 | |
| CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-41698000 | |
| CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-24116000 | |
| CY2020 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
483000 | |
| CY2019 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
578000 | |
| CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-145000 | |
| CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
75000 | |
| CY2020 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
338000 | |
| CY2019 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
653000 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-41360000 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23463000 | |
| CY2020 | us-gaap |
Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
|
7858000 | |
| CY2019 | imra |
Net Income Loss Attributable To Common Stockholders Basic And Diluted
NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted
|
-23463000 | |
| CY2020 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-3.53 | |
| CY2019 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
702455 | |
| CY2020 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-41388000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-26316000 | |
| CY2019 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
32000 | |
| CY2020 | us-gaap |
Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
|
7858000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
|
7858000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
94893000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
76526000 | |
| CY2020 | imra |
Stock Issued During Period Value Stock Options Exercised And Issuance Of Stock Under Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndIssuanceOfStockUnderEmployeeStockPurchasePlan
|
1021000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2231000 | |
| CY2020 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-28000 | |
| CY2019 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
1394000 | |
| CY2020 | us-gaap |
Depreciation
Depreciation
|
97000 | |
| CY2019 | us-gaap |
Depreciation
Depreciation
|
33000 | |
| CY2020 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-122000 | |
| CY2019 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
19000 | |
| CY2020 | us-gaap |
Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
|
465000 | |
| CY2020 | imra |
Reclassification Of Deferred Offering Costs From Other Assets To Additional Paid In Capital
ReclassificationOfDeferredOfferingCostsFromOtherAssetsToAdditionalPaidInCapital
|
-2144000 | |
| CY2020 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
60000 | |
| CY2019 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
88000 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
313000 | |
| CY2019 | imra |
Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
|
60000 | |
| CY2020 | imra |
Property And Equipment Purchases Included In Accrued Expenses
PropertyAndEquipmentPurchasesIncludedInAccruedExpenses
|
12000 | |
| CY2019 | imra |
Property And Equipment Purchases Included In Accrued Expenses
PropertyAndEquipmentPurchasesIncludedInAccruedExpenses
|
335000 | |
| CY2020 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-28000 | |
| CY2020Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
88000 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
750000 | |
| CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1748000 | |
| CY2019 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1305000 | |
| CY2020 | us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
-24000 | |
| CY2019 | us-gaap |
Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
|
100000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-37398000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-21877000 | |
| CY2020 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
47500000 | |
| CY2019Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
88000 | |
| CY2020 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of the Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMARA Inc. (“IMARA” or the “Company”) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, which have significant unmet medical need. The Company was incorporated in January 2016 under the laws of the State of Delaware, and its principal offices are in Boston, Massachusetts. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company’s sole product candidate currently under development, IMR-687, as well as any other product candidates the Company may develop, will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company effected a 1-for-6.299 reverse stock split of the Company’s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company’s outstanding series of Series Seed convertible preferred stock (“Series Seed Preferred Stock”), Series A convertible preferred stock (“Series A Preferred Stock”), Series B convertible preferred stock (“Series B Preferred Stock”), collectively referred to as “Preferred Stock.”. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to the reverse stock split, including reclassifying an amount equal to the change in par value of common stock to additional paid-in capital.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 25, 2020, the Company issued and sold 1,562,994‬ shares of Series B Preferred Stock at a price of $10.9722 per share, upon a waiver of specified milestone conditions from the holders of a majority of the shares then held by holders of Series B Preferred Stock, and raised approximately $17.1 million in net proceeds after deducting less than $0.1 million of issuance costs.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 16, 2020, the Company completed an initial public offering (“IPO”) of its common stock and issued and sold 4,700,000 shares of common stock at a public offering price of $16.00 per share, resulting in gross proceeds of $75.2 million. On April 13, 2020, the Company issued and sold an additional 705,000 shares of common stock pursuant to the exercise of the underwriters’ option to purchase additional shares for aggregate gross proceeds of $11.3 million. Inclusive of the exercise by the underwriters of their option to purchase additional shares, the Company received approximately $76.5 million in net proceeds from the IPO after deducting $10.0 million of underwriting discounts and commissions and offering expenses.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the IPO, all 70,378,661 shares of outstanding Preferred Stock automatically converted into 11,172,955 shares of common stock. Upon conversion of the convertible Preferred Stock, the Company reclassified the carrying value of the convertible Preferred Stock to common stock and additional paid-in capital. </p> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity<font style="font-weight:normal;font-style:normal;"> </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred recurring negative cash flows since inception and has funded its operations primarily from the sale of Preferred Stock. As of December 31, 2020, the Company had cash, cash equivalents, and investments of $88.2 million and an accumulated deficit of $96.1 million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes its cash, cash equivalents and investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of filing this Annual Report on Form 10-K. The Company will need additional funding to support its planned operating activities. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;"> </p> | |
| CY2020 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
64203000 | |
| CY2019 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
23920000 | |
| CY2020 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
18000 | |
| CY2019 | us-gaap |
Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
|
140000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-16721000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-24060000 | |
| CY2020 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
80427000 | |
| CY2020 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1022000 | |
| CY2020 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1718000 | |
| CY2019 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
1996000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
96881000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
43579000 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
42762000 | |
| CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-2358000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
5024000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
7382000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
47786000 | |
| CY2020 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
94893000 | |
| CY2020 | imra |
Accretion Of Redeemable Convertible Preferred Stock To Redemption Value
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValue
|
-7858000 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
4000 | |
| CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.85%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, accrued research and development expenses, stock-based compensation expense, the fair value of the common stock and Preferred Stock and income taxes. Actual results could differ materially from those estimates. </p> | |
| CY2020 | us-gaap |
Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
|
1-for-6.299 | |
| CY2020Q1 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.159 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
75200000 | |
| CY2020Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
11300000 | |
| CY2020 | imra |
Underwriting Discounts And Commissions And Offering Expenses
UnderwritingDiscountsAndCommissionsAndOfferingExpenses
|
10000000 | |
| CY2020Q1 | us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
70378661 | |
| CY2020Q1 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
11172955 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
88200000 | |
| CY2020 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2019Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
2100000 | |
| CY2020Q4 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
0 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
23939000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
32000 | |
| CY2020Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
0 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
0 | |
| CY2020Q4 | us-gaap |
Off Balance Sheet Credit Loss Liability
OffBalanceSheetCreditLossLiability
|
0 | |
| CY2019Q4 | us-gaap |
Off Balance Sheet Credit Loss Liability
OffBalanceSheetCreditLossLiability
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2019Q4 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2020Q4 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2019Q4 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2019 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | |
| CY2020 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2019 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | |
| CY2020Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
40520000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
479000 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
475000 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
130000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
33000 | |
| CY2020Q4 | imra |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
2732000 | |
| CY2019Q4 | imra |
Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
|
1106000 | |
| CY2020Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
1090000 | |
| CY2019Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
802000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
355000 | |
| CY2019Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
330000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
99000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
302000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4276000 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2540000 | |
| CY2019 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | |
| CY2020 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
200000 | |
| CY2020 | us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
In May 2019, the Company entered into a new operating lease agreement for office space totaling 4,210 square feet, located in Boston, Massachusetts with a 62-month term. | |
| CY2019Q2 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P62M | |
| CY2019Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
300000 | |
| CY2019Q4 | us-gaap |
Security Deposit
SecurityDeposit
|
100000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
273000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
278000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
284000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
229000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
1064000 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
70378661 | |
| CY2019Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
60533313 | |
| CY2019Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
60533313 | |
| CY2019Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
77764000 | |
| CY2019Q4 | us-gaap |
Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
|
80061000 | |
| CY2019Q4 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
9609961 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020 | us-gaap |
Dividends Cash
DividendsCash
|
0 | |
| CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
1302038 | |
| CY2019Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
9838813 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1863117 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
759139 | |
| CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
265945 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
420679 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1935632 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
602986 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.60 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
19.80 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.34 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.02 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.85 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
4.34 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y10M24D | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M20D | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P6Y5M1D | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
15151000 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
24260000 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
10678000 | |
| CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
12.95 | |
| CY2019 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
3.46 | |
| CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2231000 | |
| CY2019 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
899000 | |
| CY2020Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
9500000 | |
| CY2020 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y2M19D | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.07 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.03 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.02 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.01 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.36 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.29 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.00 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.00 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
24657000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
13284000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
3948000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
1020000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
686000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
246000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
545000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
611000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
272000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
200000 | |
| CY2020Q4 | imra |
Deferred Tax Assets Lease Incentive Liability
DeferredTaxAssetsLeaseIncentiveLiability
|
17000 | |
| CY2019Q4 | imra |
Deferred Tax Assets Lease Incentive Liability
DeferredTaxAssetsLeaseIncentiveLiability
|
21000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
42000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
31000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
30167000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
15413000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
30149000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
15385000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
18000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
28000 | |
| CY2020Q4 | imra |
Deferred Tax Liabilities Tenant Improvement Allowance
DeferredTaxLiabilitiesTenantImprovementAllowance
|
17000 | |
| CY2019Q4 | imra |
Deferred Tax Liabilities Tenant Improvement Allowance
DeferredTaxLiabilitiesTenantImprovementAllowance
|
21000 | |
| CY2020Q4 | imra |
Deferred Tax Liabilities Unrealized Gains Or Losses On Investments
DeferredTaxLiabilitiesUnrealizedGainsOrLossesOnInvestments
|
1000 | |
| CY2019Q4 | imra |
Deferred Tax Liabilities Unrealized Gains Or Losses On Investments
DeferredTaxLiabilitiesUnrealizedGainsOrLossesOnInvestments
|
7000 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
18000 | |
| CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
28000 | |
| CY2020 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
14800000 | |
| CY2020Q4 | imra |
Uncertain Tax Position
UncertainTaxPosition
|
0 |
